Endometriosis supplement protocol — what the evidence actually shows
Endometriosis is a chronic estrogen-dependent inflammatory disease in which endometrial-like tissue grows outside the uterus, causing dysmenorrhoea, dyspareunia, pelvic pain, and infertility. It affects roughly 1 in 10 women of reproductive age, with an average diagnostic delay of 7–10 years that is itself a major source of harm. The supplement layer is small but real: omega-3, NAC, curcumin, and vitamin D have trial signals on pain and inflammatory markers. None of these substitute for medical or surgical management — hormonal suppression (combined contraceptive pills, progestins, GnRH agonists/antagonists) and laparoscopic excision by an endometriosis specialist remain the evidence-based core treatments.
Supplements are adjuncts for endometriosis pain and inflammation, never a replacement for the evidence-based core of hormonal suppression, specialist excision surgery, and pain management. The best-studied option is omega-3 EPA/DHA, where dysmenorrhoea trials show modest but consistent reductions in pain scores and NSAID use; NAC and vitamin D (when deficient) have smaller signals, and the Porpora trial of NAC reported some reduction in endometrioma size. The key caveat is that none of these treat the disease tissue itself, so confirm the diagnosis with an endometriosis-specialist gynaecologist and treat the supplement layer as a bolt-on, reassessed at 12 weeks.
Read this first. Persistent or progressive pelvic pain, severe dysmenorrhoea, deep dyspareunia, infertility, or cyclical bowel/bladder symptoms warrant evaluation — endometriosis is commonly missed. Refer to a gynaecologist with endometriosis-specific expertise; excision surgery by a specialist is meaningfully different in outcomes from generalist ablation. Supplements do not treat endometriosis tissue; they may help with inflammation and pain as adjuncts.
What actually has trial evidence as an adjunct
Omega-3 EPA/DHA
1.5–2 g EPA+DHA combined/day with a fatty meal
Omega-3 fatty acids modulate prostaglandin balance toward less inflammatory series-3 prostaglandins. Several trials in dysmenorrhoea (including endometriosis-associated pain) show reductions in pain scores and NSAID consumption. Effect size is modest but consistent. Combine with anti-inflammatory dietary pattern.
N-Acetyl Cysteine (NAC)
600 mg three times daily; 3-month trial
The Porpora 2013 Italian trial reported that NAC 600 mg t.i.d. for 3 months produced reduction in endometrioma size in some users and improvements in pain scores. The trial was small and unblinded; subsequent replication is limited. Reasonable as an adjunct given low risk and modest cost; not a substitute for surgery in symptomatic endometriomas.
Curcumin (bioavailable form)
500 mg b.i.d. of a bioavailable curcumin (phytosome, BCM-95, or similar)
Mechanistic plausibility (NF-κB inhibition, prostaglandin modulation, anti-angiogenic effects); small clinical trials specifically in endometriosis are limited but suggestive. Reasonable adjunct as part of an inflammation-focused approach. Caution with anticoagulants.
Vitamin D3 (to target)
2,000–4,000 IU/day to a 25-OH-D target of 30–50 ng/mL
Vitamin D deficiency is over-represented in endometriosis cohorts; small trials show modest pain reduction with repletion in deficient users. Test 25-OH-D first.
Iron (ferrous bisglycinate) for menstrual blood loss-related anemia
Ferrous bisglycinate 30 mg elemental every other day, if ferritin < 30–50 ng/mL
Heavy menstrual bleeding and chronic blood loss are common; iron-deficiency anemia is frequently undertreated. Test ferritin and hemoglobin; replete if deficient.
Palmitoylethanolamide (PEA)
300–600 mg/day; 3-month trial
PEA is an endogenous fatty acid amide with anti-inflammatory and analgesic properties (PPAR-α agonist). Small trials in pelvic pain and endometriosis (Indraccolo 2010 and others) suggest modest pain reduction. Reasonable in users with persistent pain despite first-line medical therapy; expensive, so a clear stopping rule is sensible.
What dominates over supplements — the actual treatment
- Hormonal suppression — combined oral contraceptive pills (continuous or extended cycle), progestin-only options (norethindrone, dienogest), levonorgestrel IUDs, GnRH antagonists (elagolix, relugolix combination therapy), and depot leuprolide reduce pain and disease activity. First-line for most users with confirmed or suspected endometriosis-associated pain.
- Specialist excision surgery — laparoscopic excision by an endometriosis specialist outperforms ablation and provides histologic diagnosis. Outcomes are surgeon-dependent.
- NSAIDs as first-line pain management — alongside hormonal suppression. Mefenamic acid, naproxen, and others.
- Pelvic floor physiotherapy — endometriosis-associated chronic pelvic pain commonly drives pelvic floor dysfunction; specialised PT reduces pain and dyspareunia.
- Multidisciplinary pain management — chronic pelvic pain often requires pain specialist input, neuromodulation (gabapentin, amitriptyline), and CBT.
- Anti-inflammatory dietary pattern — Mediterranean-style; observational evidence suggests modest pain benefit; ultra-processed food reduction is reasonable.
- Fertility care — IVF is often the most effective fertility treatment in endometriosis; coordinated reproductive endocrinology and endometriosis-specialist care.
What to skip
- "Estrogen detox" supplements (DIM, calcium-D-glucarate, indole-3-carbinol high-dose) — endometriosis is estrogen-dependent but the supplement-route "detox" is not a recognised endometriosis treatment; medical hormonal suppression is. DIM can affect cytochrome P450 metabolism of medications.
- Generic "women's hormone balance" blends with vitex, dong quai, and various honourable mentions — vitex in particular has unclear effects in endometriosis and may be counterproductive.
- Wild yam creams as "natural progesterone" — wild yam diosgenin is NOT converted to progesterone in the human body.
- Castor oil packs as primary treatment — popular in alternative medicine for endometriosis; no RCT evidence.
- Mega-dose iodine for "estrogen detoxification" — wildly inappropriate; iodine excess causes thyroid dysfunction.
- Cannabis / CBD as a primary endometriosis treatment — modest signals on pelvic pain in observational data; not a substitute for medical management.
- Soy isoflavones in significant amounts — endometriosis-specific evidence is mixed; some concern about phytoestrogen effect in an estrogen-dependent disease. Modest dietary soy is fine; high-dose isoflavone supplements should be discussed with the gynaecologist.
What to track
Pain (VAS or NRS scale, dysmenorrhoea severity, dyspareunia, non-cyclical pelvic pain) is the standard endpoint. Health-related quality of life measures (EHP-30 is endometriosis-specific) capture impact. Cyclical patterns matter — many users find tracking symptoms across their cycle clarifies what's working. Reassess at 12 weeks of any supplement intervention; supplements are adjuncts, so the primary trend should be evaluated alongside medical/surgical management.
Practical quick-start. Establish or confirm diagnosis with a gynaecologist with endometriosis-specific expertise. First-line treatment is medical hormonal suppression with NSAIDs as needed; specialist excision when symptoms persist or fertility is the goal. Pelvic floor physiotherapy for chronic pelvic pain. For the supplement layer as adjunct: omega-3 EPA+DHA 1.5–2 g/day + vitamin D3 to target if deficient + bioavailable curcumin 500 mg b.i.d. + consider NAC 600 mg t.i.d. for 3 months. Track ferritin and replete if low. Reassess at 12 weeks.